Page 5 - Nick Benedetto News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA

Anticipated FDA action date in Q4 2023; if approved, combined launch for Erosive GERD and H. pylori indications planned before year endIf approved, vonoprazan would be the first innovative acid. | May 23, 2023

United statesNick benedettoTerrie curranEric sciorilliDrug administrationPhathom pharmaceuticals incPhathom pharmaceuticalsExchange commissionCompany annual report on formNew drug applicationComplete response letterChief executive officerErosive esophagitisAnnual reportPrivate securities litigation reform actNc stock exchange

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 12, 2023 Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced. | April 12, 2023

New yorkUnited statesHc wainwright bioconnectNick benedettoEric sciorilliPhathom pharmaceuticals incPhathom pharmaceuticalsAnnual needham virtual healthcare conferenceBioconnect investor conferenceNc stock exchangePress releaseAstrointestinal phat us71722w1071

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBaden wübergTerrie curranJames topperNick benedettoExchange commissionCompany annual report on formPhathom pharmaceuticals incDuring the american college of gastroenterologyPhathom pharmaceuticalsPartner at frazier life sciencesFrazier lifesciences acquisition corporationErosive esophagitisChief executive officerRecent business updatesDosing phase

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNick benedettoAzmi nabulsiConsensus groupCompany annual report on formExchange commissionPhathom pharmaceuticals incPhathom pharmaceuticalsDosing phaseNew drug applicationChief operating officerNon erosive gastroesophageal reflux diseaseCutaneous adverse reactionsDiagnostic investigationsNeuroendocrine tumorsPrecautions due